Top of this page
Skip navigation, go straight to the content
UCB is a global biopharmaceutical company focused on creating value for people living with severe diseases in immunology and neurology.
We work with stakeholders to address the unmet needs of patients and caregivers, helping them to achieve their goals and to live the lives they want. UCB is on a journey to become the patient-preferred biopharma leader by delivering medicines and solutions that improve lives. Our commitment to value is a promise to bring together the talent, expertise, tools and scientific know-how required to serve patients in need.
At UCB, we take our responsibility
to the planet very seriously.
UCB Ventures, our strategic corporate venture fund established in 2017
Twitter Feed
-
We're working hard to ensure our operations are #carbonneutral by 2030. Find out how in our Green Strategy ????#sustainability #InspiredByPatients #DrivenByScience https://t.co/6WEtqwh9AV https://t.co/8DWHAtG9U1
— UCB News (@ucb_news) 16.08.2019 -
#DYK we are around 7,500 people from more than 70 nationalities spanning all four corners of the globe ????#InspiredByPatients #DrivenByScience https://t.co/LcOv2rPIhF https://t.co/aQW1B7KE1u
— UCB News (@ucb_news) 14.08.2019 -
UCB's Erik Janssen has provided his insights about how convergence in health and technology can add value to patients. https://t.co/esUTFjmZZ9 https://t.co/T8CJ19s41U
— UCB News (@ucb_news) 09.08.2019
